INTERNATIONAL JOURNAL OF COGNITIVE NEUROSCIENCE AND PSYCHOLOGY

THE GROWING THREAT OF ANTIBIOTIC RESISTANCE: MECHANISMS, CAUSES, CONSEQUENCES, AND SOLUTIONS

Zulfkar Qadrie
Department of Pharmacology, Government Medical College Baramulla

Humaira Ashraf
Department of Animal Nutrition, SKUAST-K, Srinagar, India

Mohd Altaf Dar
Department of Pharmacology, CT Institute of Pharmaceutical Sciences, PTU, Jalandhar Punjab

Afshana Qadir
Nursing Tutor, Government College of Nursing Baramulla

Abstract: Antibiotic resistance (ABR) is a rapidly growing global health threat that jeopardizes public health, medical progress, and the global economy. This paper explores the mechanisms driving ABR, its contributing factors, its effects on human health, and global efforts to tackle the issue. The resistance phenomenon is primarily caused by genetic mutations, horizontal gene transfer, efflux pumps, and biofilm formation in bacteria. These processes enable bacteria to evade the effects of antibiotics, making infections harder to treat. Several factors contribute to the spread of ABR. The overuse and misuse of antibiotics in both healthcare and agriculture are critical drivers, as are poor infection control practices and the global movement of people and goods. These factors facilitate the rapid dissemination of resistant bacteria across countries and continents. The consequences of ABR are severe, resulting in prolonged hospital stays, higher mortality rates, and a significant economic burden due to increased healthcare costs and lost productivity. To combat ABR, strategies such as antimicrobial stewardship, the development of new antibiotics, and alternative therapies are essential. Moreover, an integrated approach is needed, encompassing global coordination, improved surveillance systems, and increased public awareness. By addressing these issues collaboratively, we can preserve the efficacy of antibiotics and safeguard their use for future generations.

Key words: Antibiotic, Resistance, Global Health, Mechanisms, Mutations, Infection Control, Overuse, Agriculture.

Introduction

Antibiotic resistance (AMR) has emerged as one of the most significant and urgent global health crises in modern times. As pathogens evolve resistance to the antimicrobial drugs that once effectively treated infections, the world faces a rising threat that compromises public health and hinders the progress of modern medicine. The continued development of antibiotic-resistant bacteria, fungi, parasites, and viruses has escalated into a pressing issue with far-reaching implications. While antibiotics were once considered miracle drugs, the rapid spread of resistance has undermined their effectiveness, turning even simple, treatable infections into potentially life-threatening conditions. Consequently, AMR is now a top priority for health organizations around the world, including the World Health Organization (WHO), which deems antibiotic resistance as one of the greatest threats to global health, food security, and development [1]. Antibiotic resistance occurs when microorganisms evolve mechanisms to withstand the effects of drugs that would typically kill or inhibit their growth. This biological phenomenon can result from genetic mutations in the microorganism's DNA or from horizontal gene transfer, in which bacteria acquire resistance genes from other bacteria. These evolutionary processes allow resistant strains to survive and multiply, rendering previously effective treatments ineffective. While AMR is primarily associated with bacteria, it can also affect other pathogens such as fungi, viruses, and parasites, contributing to a wide range of healthcare challenges. The development of antibiotic resistance has been exacerbated by various human-driven factors. One of the primary contributors to the rise of AMR is the overuse and misuse of antibiotics in both healthcare settings and agriculture. In healthcare, the unnecessary prescription of antibiotics for viral infections, for which they are ineffective, has contributed to the development of resistance [2]. Additionally, the improper use of antibiotics, such as not completing prescribed courses, creates an environment where bacteria can adapt and survive. In agriculture, the widespread use of antibiotics in livestock farming for growth promotion and disease prevention has led to the emergence of antibiotic-resistant strains that can transfer to humans through the food chain. Another significant factor contributing to the spread of AMR is poor infection control practices in healthcare settings. Inadequate hygiene, improper sterilization of medical equipment, and insufficient isolation of infected patients can facilitate the transmission of resistant pathogens within hospitals and clinics. This is particularly concerning in environments where vulnerable populations, such as the elderly, immunocompromised individuals, and newborns, are at high risk of infections. The global movement of people and goods also plays a crucial role in the spread of antibiotic-resistant infections. In an interconnected world, resistant pathogens can quickly travel across borders, making it difficult for countries to contain outbreaks. As individuals travel internationally, they may inadvertently carry resistant bacteria, spreading them to new regions. The increasing volume of global trade further exacerbates the situation, as resistant pathogens can be transmitted via contaminated food, water, and goods [3].

The consequences of antibiotic resistance are severe and wide-ranging. In healthcare, AMR leads to longer hospital stays, increased medical costs, and higher mortality rates. When infections cannot be treated effectively with standard antibiotics, patients may require more expensive and potentially toxic alternative treatments. In many cases, infections caused by resistant pathogens can lead to complications that are difficult to manage, including organ failure, sepsis, and death. For example, common procedures such as surgeries, cancer treatments, and organ transplants, which rely on effective antibiotics to prevent infections, become riskier and more complex in the face of AMR. Beyond its impact on individual health, antibiotic resistance also poses a significant economic burden. The WHO estimates that by 2050, AMR could lead to an additional 10 million deaths per year and cost the global economy $100 trillion. The loss of effective antibiotics would reduce the ability to manage infectious diseases, leading to increased morbidity and mortality, decreased labor force productivity, and higher healthcare costs. Additionally, the agricultural sector would face challenges in managing livestock diseases, which could result in reduced food security and higher prices [4]. Addressing the growing problem of antibiotic resistance requires a multifaceted approach that includes both immediate and long-term strategies. A key aspect of combating AMR is antimicrobial stewardship, which involves optimizing the use of antibiotics to ensure they are prescribed only when necessary and in the correct dosages. Efforts to improve infection prevention and control in healthcare settings are also critical, as these measures can reduce the transmission of resistant pathogens. Strict hygiene protocols, proper sterilization of medical equipment, and the isolation of infected patients can help minimize the spread of AMR within hospitals and clinics [5].

Mechanisms of Antibiotic Resistance

The development of antibiotic resistance in microorganisms is a complex biological process that involves various mechanisms, allowing pathogens to survive in the presence of antibiotics and rendering previously effective treatments ineffective. These mechanisms, which help bacteria and other microorganisms adapt to the selective pressure exerted by antibiotics, can be categorized into several key strategies. One of the primary mechanisms behind antibiotic resistance is **genetic mutations**. Bacteria can acquire mutations in their genetic material that confer resistance to specific antibiotics. These mutations can occur spontaneously and are typically random, but when an antibiotic is applied, the susceptible bacteria are killed, while those with mutations that provide resistance may survive and proliferate. Over time, these resistant bacteria multiply and create a population of pathogens that are no longer susceptible to the drug. For example, mutations in the gene encoding

DNA gyrase can provide resistance to fluoroquinolones, a class of antibiotics commonly used for treating respiratory and urinary infections [6]. As these mutated strains continue to replicate, the resistance to fluoroquinolones becomes more widespread. Another significant mechanism is **horizontal gene transfer (HGT)**, the process by which bacteria exchange genetic material, enabling them to acquire resistance traits without the need for direct descent. HGT occurs through three primary mechanisms: conjugation (bacterial mating), transformation (uptake of naked DNA), and transduction (gene transfer via bacteriophages). This allows bacteria to rapidly share and spread resistance genes within and across populations. For example, genes responsible for resistance to beta-lactam antibiotics, such as penicillin, can be transferred between bacteria via plasmids, small circular DNA molecules. This exchange accelerates the proliferation of resistant strains across diverse bacterial species and environments, making the spread of AMR even more pervasive [7]. **Efflux pumps** are another important mechanism by which bacteria develop resistance to antibiotics. These are specialized proteins found in the bacterial cell membrane that actively expel antibiotics from inside the cell. By reducing the intracellular concentration of the drug, efflux pumps make it difficult for antibiotics to reach therapeutic levels within the bacteria, effectively rendering the drug ineffective. Efflux pumps are particularly problematic because they are often capable of expelling a broad range of antibiotics, leading to **multi-drug resistance** (MDR). For example, the bacterium *Pseudomonas aeruginosa* uses efflux pumps to resist a variety of antibiotics, making it especially challenging to treat in hospital settings, particularly in patients with weakened immune systems. The presence of these efflux pumps contributes to the difficulty of treating such infections and complicates hospital infection control efforts [8].

Enzymatic degradation or modification is another prominent mechanism of resistance. Some bacteria produce enzymes that can directly degrade or modify antibiotics, thereby inactivating them. One of the most widely known examples is **beta-lactamase**, an enzyme that breaks down the beta-lactam ring structure in beta-lactam antibiotics like penicillin, rendering them ineffective. Beta-lactamase is produced by several bacteria, including *Escherichia coli* and *Klebsiella pneumoniae*. While beta-lactamase inhibitors have been developed to counteract this mechanism, resistant strains continue to evolve that produce enzymes capable of breaking down even these inhibitors, further exacerbating the global resistance crisis. In some cases, bacteria can evade the effects of antibiotics through **target modification [9]**. Antibiotics work by binding to specific targets in bacterial cells, such as enzymes or components of the cell wall. By mutating or modifying these targets, bacteria can prevent antibiotics from binding effectively, thereby escaping their lethal effects. For example, *Staphylococcus aureus* strains that are resistant to methicillin (MRSA) produce a modified penicillin-binding protein (PBP2a) that has a lower affinity for methicillin. This alteration allows MRSA to resist the effects of beta-lactam antibiotics, making it a particularly dangerous pathogen to treat. Lastly, **biofilm formation** plays a critical role in antibiotic resistance. Biofilms are dense clusters of bacterial cells that secrete extracellular polymeric substances (EPS), which create a protective layer around the bacteria. The biofilm matrix shields the bacteria from antibiotics, making it difficult for the drugs to penetrate and reach effective concentrations [10]. Additionally, bacteria within biofilms often exhibit altered metabolic activity, which makes them less susceptible to antibiotics that target rapidly growing cells. Biofilm-associated infections are especially problematic in medical settings, where they can form on devices like catheters, prosthetics, and heart valves. *Pseudomonas aeruginosa*, a common biofilm-forming bacterium, is notorious for causing chronic infections in patients with cystic fibrosis, further complicating treatment efforts. These biofilm-associated infections are not only harder to treat but also increase the risk of persistent, recurring infections that require prolonged or more intensive treatment. Together, these mechanisms—genetic mutations, horizontal gene transfer, efflux pumps, enzymatic degradation, target modification, and biofilm formation—combine to form a multifaceted defense strategy for bacteria, helping them survive in the face of antibiotic treatment. As bacteria evolve new resistance mechanisms, the development of novel antibiotics and alternative therapies becomes increasingly crucial to combatting the global threat of antibiotic resistance. Understanding these mechanisms is essential for developing more effective treatments and strategies to prevent the further spread of AMR [11].

Causes of Antibiotic Resistance

The rise in antibiotic resistance is a direct consequence of several human activities and practices that facilitate the misuse and overuse of antibiotics. These behaviors have accelerated bacterial evolution and the spread of resistant strains, which poses a serious threat to global public health. The primary causes of antibiotic resistance stem from practices in healthcare, agriculture, self-medication, inadequate infection control, global travel, and environmental contamination. Each of these factors contributes to the growing challenge of combating antibiotic resistance and preventing its further spread. **Overuse and misuse of antibiotics** are among the most significant contributors to the rise of antibiotic resistance [12]. In human medicine, antibiotics are often prescribed unnecessarily for viral infections such as the common cold or flu, even though these medications are ineffective against viruses. The over-prescription of antibiotics leads to the unnecessary exposure of bacteria to these drugs, encouraging the development of resistance. Additionally, patients frequently fail to complete their full course of antibiotics, leaving some bacteria alive. These surviving bacteria, which may have developed some resistance, can mutate further and become even more resistant to treatment. In the agricultural sector, antibiotics are routinely administered to livestock not only for treating diseases but also to promote growth. This overuse of antibiotics in animals contributes to the development of resistant bacteria in animals that can later be transmitted to humans through direct contact, consumption of contaminated meat, or environmental exposure [13].

Self-medication and the **incomplete courses** of antibiotics further exacerbate the problem. In many parts of the world, particularly in developing countries, individuals often purchase antibiotics without a prescription and use them for conditions that may not even require them, such as mild infections or viral illnesses. This practice of self-medication leads to the misuse of antibiotics, exposing bacteria to these drugs without proper guidance on appropriate use. Additionally, many patients who are prescribed antibiotics fail to complete the full course of treatment. When patients stop taking antibiotics prematurely, they leave behind a subset of bacteria that may have developed some resistance [14]. These remaining bacteria are more likely to develop further resistance and cause more difficult-to-treat infections in the future. **Poor infection control and sanitation** in healthcare settings also play a crucial role in the spread of resistant bacteria. In hospitals, clinics, and long-term care facilities, inadequate infection control measures, such as improper sanitation and insufficient sterilization of medical instruments, allow resistant bacteria to thrive. Without proper infection control, resistant pathogens can spread rapidly among patients and healthcare workers, exacerbating the problem. Furthermore, the lack of appropriate isolation procedures for patients with resistant infections can lead to cross-contamination and transmission of these pathogens within the healthcare facility [15]. The impact of **global travel and trade** cannot be understated in the context of antibiotic resistance. As people, animals, and goods move rapidly across international borders, resistant bacteria are easily transmitted between regions. Travelers who acquire resistant infections abroad may unknowingly bring them back to their home countries, where they can spread to others, creating local outbreaks. The global trade of livestock and food products also facilitates the movement of resistant bacteria. Bacteria that are resistant to antibiotics in animals can be transported through the trade of meat and other animal products, leading to the introduction of resistant strains into new geographic areas and populations. Finally, **environmental contamination** plays an increasingly important role in the proliferation of antibiotic resistance. Antibiotic residues from pharmaceutical manufacturing, agricultural practices, and healthcare waste can enter the environment through wastewater, sewage, and runoff. Once these antibiotic residues enter natural water sources, they create a reservoir for resistant bacteria to grow. These resistant bacteria can then exchange resistance genes with other bacteria, increasing the overall burden of antibiotic resistance [16]. Contaminated environments, including rivers, lakes, and soil, act as breeding grounds for resistance, further spreading resistance to bacteria that live in the environment, and potentially introducing it back into human populations through the food chain or water supply [17].

Consequences of Antibiotic Resistance

The consequences of antibiotic resistance are profound and pose a significant threat not only to individual health but also to global public health and economic stability. As antibiotic-resistant bacteria continue to spread, the implications for society at large are becoming increasingly dire. The most concerning consequences of this issue include increased mortality and morbidity, longer hospital stays and higher healthcare costs, limited treatment options, threats to medical advancements, and the potential for a global health crisis**. Increased mortality and morbidity** is one of the most alarming outcomes of antibiotic resistance. As bacteria evolve to resist the effects of common antibiotics, infections that were once easily treatable become harder to manage. Infections caused by resistant bacteria are associated with higher mortality rates and prolonged illness, which can lead to more severe health complications. For example, the emergence of multidrug-resistant tuberculosis (MDR-TB) has made what was once a treatable and manageable disease far more deadly and difficult to treat. These resistant infections often require more intensive treatment, increasing the risk of adverse outcomes for patients [18].

The **longer hospital stays and higher healthcare costs** resulting from antibiotic resistance are another significant burden on healthcare systems. Patients who develop resistant infections typically require longer hospitalizations, often needing specialized care in intensive care units. These extended stays increase the overall cost of treatment, as patients need more intensive monitoring, more expensive drugs, and possibly prolonged use of medical equipment. This situation places a financial strain not only on patients and their families but also on healthcare systems, which must allocate more resources to manage these complex cases. The additional costs further complicate an already overstretched healthcare infrastructure, especially in countries with limited resources [13]. **Limited treatment options** also present a major challenge in the face of growing antibiotic resistance. As bacteria continue to evolve resistance, the number of effective antibiotics available to treat infections diminishes. The development of new antibiotics, however, has slowed significantly in recent years, leaving fewer treatment options for patients. This lack of viable alternatives creates a medical crisis where doctors have fewer tools at their disposal to fight infections. In some cases, doctors may be forced to resort to older, less effective, and potentially more toxic antibiotics, further complicating the treatment process and increasing the risk of side effects. The inability to effectively treat infections ultimately leads to worse patient outcomes and a higher likelihood of complications or death [19].

The rise of antibiotic resistance also poses a **threat to medical advancements** that rely on the effectiveness of antibiotics. Modern medical procedures such as organ transplants, chemotherapy, and major surgeries depend on the ability to prevent and treat infections effectively. Antibiotics are crucial in preventing infections during and after these procedures, as patients are often immunocompromised and highly vulnerable to infections. However, the spread of resistant bacteria significantly increases the risk of infections in such patients, making these procedures more dangerous. The diminished ability to treat infections in these settings jeopardizes the success of many life-saving treatments, hindering medical progress and reducing the overall quality of healthcare [20]. Finally, antibiotic resistance has the potential to evolve into a **global health crisis**. If left unchecked, the spread of antimicrobial resistance could result in millions of deaths annually. According to a report by the UK government, antimicrobial resistance could cause up to 10 million deaths each year by 2050, surpassing cancer as the leading cause of death worldwide. The economic impact of this crisis would be devastating, leading to trillions of dollars in lost productivity, higher healthcare costs, and greater economic inequality. The global economy would bear the weight of antibiotic resistance, as countries struggle to manage the rising costs of healthcare and the loss of human capital due to untreatable infections. Furthermore, the global nature of the issue means that antibiotic resistance is not confined to any one country or region. The movement of people and goods across borders facilitates the spread of resistant pathogens, making it a truly global issue that requires coordinated efforts from governments, health organizations, and the private sector [21-25].

Solutions to Combat Antibiotic Resistance

The fight against antibiotic resistance requires a coordinated and comprehensive global approach that integrates prevention, education, innovation, and regulation. This multifaceted strategy must involve efforts across healthcare systems, agriculture, public awareness campaigns, and international collaboration. To effectively combat antibiotic resistance, several key strategies must be implemented. **Antimicrobial stewardship and responsible use** are crucial components in the fight against antibiotic resistance. Antimicrobial stewardship programs focus on the responsible use of antibiotics, ensuring that they are prescribed only when necessary, in the correct dose, and for the appropriate duration. These programs emphasize the importance of healthcare professionals being trained to recognize when antibiotics are not needed and to explore alternative treatments when possible. By reducing unnecessary antibiotic prescriptions, antimicrobial stewardship aims to slow down the development of resistant bacteria [25-30]. This strategy also includes educating patients about the importance of completing prescribed antibiotic courses, avoiding the use of antibiotics for viral infections, and not demanding antibiotics when they are not needed. **Public awareness and education** play a vital role in tackling antibiotic resistance. Public education campaigns are essential for raising awareness about the dangers of misuse and overuse of antibiotics. These campaigns need to target both healthcare providers and the general public to promote understanding about the limited effectiveness of antibiotics for viral infections, and how misuse contributes to the spread of resistance. By educating the public on the proper use of antibiotics and the risks associated with self-medication, people can make more informed decisions about their health and reduce unnecessary antibiotic consumption. Healthcare providers must also be educated on the latest guidelines for prescribing antibiotics, ensuring that they adhere to best practices [30-35].

Infection prevention and control are key aspects of any strategy to combat antibiotic resistance. By preventing the spread of infections, the need for antibiotics can be minimized. Simple but effective measures, such as improving sanitation and hygiene practices, promoting regular handwashing, and using proper infection control procedures in healthcare settings, can significantly reduce the transmission of resistant bacteria. Isolating patients with known resistant infections and ensuring the sterilization of medical instruments are also vital steps in preventing the spread of resistant pathogens [36]. Additionally, the promotion of vaccination programs can prevent infections in the first place, reducing the need for antibiotics. **Regulating the use of antibiotics in agriculture** is another critical strategy in fighting antibiotic resistance. The use of antibiotics in agriculture, particularly for growth promotion in healthy animals, is a significant contributor to the development of resistant bacteria. Antibiotic use in food production should be strictly limited to the treatment of diagnosed infections, and their use in promoting growth should be banned. Encouraging sustainable farming practices, improving animal welfare, and promoting alternatives to antibiotics, such as vaccines and probiotics, are essential to reduce the reliance on antibiotics in agriculture. By regulating the use of antibiotics in livestock, the spread of resistant bacteria in the food chain can be controlled, ultimately protecting human health [37].

The development of new antibiotics and alternative therapies is urgent and necessary to replace antibiotics that have become ineffective due to resistance. Governments, research institutions, and pharmaceutical companies must prioritize investment in the research and development of novel antibiotics. However, the development of new antibiotics has slowed significantly in recent years, and there is a need for policies that incentivize innovation in this area. Additionally, exploring alternative therapies, such as bacteriophage therapy, which uses viruses to target and kill bacteria, offers hope in treating resistant infections. Other potential alternatives include antimicrobial peptides, vaccines, and the use of non-traditional medicine [38]. By diversifying treatment options, the reliance on traditional antibiotics can be reduced, slowing the development of resistance. Finally, **global collaboration** is essential in the fight against antibiotic resistance. This issue transcends national borders, and therefore requires a global response. Governments, international organizations like the World Health Organization (WHO), and researchers must work together to develop strategies to combat antibiotic resistance on a global scale. Coordinating surveillance programs to track resistance patterns, sharing research findings, and implementing policies that regulate antibiotic use across borders are vital steps in addressing this global health threat. By strengthening international collaboration, the spread of antibiotic-resistant pathogens can be better controlled, and resources can be pooled to develop effective solutions [38-40].

Conclusion

Antibiotic resistance is an urgent and complex global challenge that has far-reaching consequences for public health, medical advancements, and the economy. The rise of resistant bacteria makes previously treatable infections harder to manage, leading to increased mortality, prolonged illness, and a higher financial burden on healthcare systems. As antibiotics lose their effectiveness, the world faces a potential public health crisis that could reverse many of the medical advancements made in the past century. Addressing this issue requires coordinated action across various sectors, including healthcare, agriculture, public policy, and the scientific community. One of the most effective strategies for combating antibiotic resistance is **investing in antimicrobial stewardship programs**. These programs focus on ensuring that antibiotics are prescribed only when necessary, in the correct doses, and for the appropriate duration. By promoting responsible antibiotic use, we can minimize the development of resistance. Additionally, improving **infection control practices** in healthcare settings—such as proper sanitation, sterilization of medical instruments, and the isolation of infected patients—plays a critical role in reducing the transmission of resistant bacteria. **Public policy** also plays a crucial role in regulating antibiotic use, particularly in agriculture, where the overuse of antibiotics in livestock contributes to the spread of resistance. Strict regulations that limit the use of antibiotics for growth promotion and encourage sustainable farming practices are necessary. Lastly, **international collaboration** is vital to address the global nature of antibiotic resistance. Countries must work together to share research, coordinate surveillance, and implement policies that regulate antibiotic use. Through these collective efforts, we can slow the spread of resistance and ensure that antibiotics remain effective for future generations.

References

1. Zehravi M, Maqbool M, Ara I. Polycystic ovary syndrome and infertility: an update. International journal of adolescent medicine and health. 2021 Jul 22;34(2):1-9.
2. Lihite RJ, Lahkar M, Das S, Hazarika D, Kotni M, Maqbool M, Phukan S. A study on adverse drug reactions in a tertiary care hospital of Northeast India. Alexandria journal of medicine. 2017 Jul 11;53(2):151-6.
3. Zehravi M, Maqbool M, Ara I. Correlation between obesity, gestational diabetes mellitus, and pregnancy outcomes: an overview. International Journal of Adolescent Medicine and Health. 2021 Jun 18;33(6):339-45.
4. Maqbool M, Bekele F, Fekadu G. Treatment strategies against triple-negative breast cancer: an updated review. Breast Cancer: Targets and Therapy. 2022 Jan 11:15-24
5. Rasool S, Maqbool M. An overview about Hedychium spicatum: a review. Journal of Drug Delivery and Therapeutics. 2019 Feb 15;9(1-s):476-80.
6. Zehravi M, Maqbool M, Ara I. Depression and anxiety in women with polycystic ovarian syndrome: a literature survey. International Journal of Adolescent Medicine and Health. 2021 Aug 23;33(6):367-73.
7. Maqbool M, Gani I, Dar MA. Anti-diabetic effects of some medicinal plants in experimental animals: a review. Asian Journal of Pharmaceutical Research and Development. 2019 Feb 15;7(1):66-9.
8. Zehravi M, Maqbool M, Ara I. Polycystic ovary syndrome and reproductive health of women: a curious association. International journal of adolescent medicine and health. 2021 Apr 21;33(6):333-7.

9. Mohd M, Maqbool M, Dar MA, Mushtaq I. Polycystic ovary syndrome, a modern epidemic: an overview. Journal of Drug Delivery and Therapeutics. 2019 May 15;9(3):641-4.
10. Maqbool M, Fekadu G, Jiang X, Bekele F, Tolossa T, Turi E, Fetensa G, Fanta K. An up to date on clinical prospects and management of osteoarthritis. Annals of Medicine and Surgery. 2021 Dec 1;72:103077.
11. Majeed A, Bashir R, Farooq S, Maqbool M. Preparation, characterization and applications of nanoemulsions: An insight. Journal of Drug Delivery and Therapeutics. 2019 Mar 15;9(2):520-7.
12. Zehravi M, Maqbool M, Ara I. Healthy lifestyle and dietary approaches to treating polycystic ovary syndrome: a review. Open Health. 2022 May 2;3(1):60-5.
13. Maqbool R, Maqbool M, Zehravi M, Ara I. Menstrual distress in females of reproductive age: a literature review. International journal of adolescent medicine and health. 2021 Jul 22;34(2):11-7.
14. Ara I, Maqbool M, Fekadu G, Hajam TA, Dar MA. Pharmaceutical significance of Nigella sativa L., a wonder herb. Journal of Applied Pharmaceutical Sciences and Research. 2020;3(4):04-13.
15. Maqbool M, Nasir N, Mustafa S. Polycystic in ovarian syndrome and its various treatment strategies. INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2018 Sep 1;5(9):8470-8.
16. Maqbool M, Zehravi M, Maqbool R, Ara I. Study of adverse drug reactions in pulmonary medicine department of a Tertiary care hospital, Srinagar, Jammu & Kashmir, India. CELLMED. 2021;11(2):8-1.
17. Ara I, Maqbool M, Bukhari B, Ara N, Hajam TA. Present status, standardization and safety issues with herbal drugs. International Journal of Research in Pharmaceutical Sciences and Technology. 2020 May 18;1(3):95-101.
18. Ara I, Maqbool M, Gani I. Reproductive Health of Women: implications and attributes. International Journal of Current Research in Physiology and Pharmacology. 2022 Nov 28:8-18.
19. Zehravi M, Maqbool R, Maqbool M, Ara I. To Identify Patterns of Drug Usage among Patients Who Seek Care in Psychiatry Outpatient Department of a Tertiary Care Hospital in Srinagar, Jammu and Kashmir, India. Journal of Pharmaceutical Research International. 2021 Jun 10;33(31A):135-40.
20. Maqbool M, Javed S, Bajwa AA. Assessment OF pain management IN postoperative cases using different scales and questionnaires. INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2019 Jan 1;6(1):983-7.
21. Ara I, Maqbool M, Zehravi M. Psychic consequences of infertility on couples: A short commentary. Open Health. 2022 Jan 1;3(1):114-9.
22. Bashir R, Maqbool M, Ara I, Zehravi M. An In sight into Novel Drug Delivery System: In Situ Gels. CELLMED. 2021;11(1):6-1.
23. Zehravi M, Maqbool M, Ara I. Teenage menstrual dysfunction: an overview. International Journal of Adolescent Medicine and Health. 2022 Sep 19;35(1):15-9.
24. Ara I, Zehravi M, Maqbool M, Gani I. A review of recent developments and future challenges in the implementation of universal health coverage policy framework in some countries. Journal of Pharmaceutical Research & Reports. SRC/JPRSR-131. DOI: doi. org/10.47363/JPRSR/2022 (3). 2022;127.
25. Maqbool M, Shabbir W, Aamir S. Adverse events of blood transfusion and blood safety in clinical practice. Indo American Journal Of Pharmaceutical Sciences. 2018 Aug 1;5(8):8254-9.
26. Maqbool M, Naeem A, Aamer S. Diabetes mellitus and its various management strategies in practice. Indo American Journal of Pharmaceutical Sciences. 2018 Aug 1;5(8):8163-+.

27. Maqbool M, Tariq S, Amjad S. Prescribing practices in pediatrics and drug utilization studies promoting pediatric health. Indo American Journal of Pharmaceutical Sciences. 2018 Aug 1;5(8):8070-6.

28. Maqbool M, Ikram U, Anwar A. Adverse drug reaction monitoring and occurrence in drugs used in pulmonary disorders. Indo American Journal Of Pharmaceutical Sciences. 2018 Aug 1;5(8):8060-5.

29. Maqbool R, Maqbool M, Zehravi M, Ara I. Acute neurological conditions during pregnancy and their management: a review. International Journal of Adolescent Medicine and Health. 2021 Aug 23;33(6):357-66.

30. Zehravi M, Maqbool M, Ara I. An overview about safety surveillance of adverse drug reactions and pharmacovigilance in India. The Indian Journal of Nutrition and Dietetics. 2021 Jul:408-18.

31. Maqbool M, Zehravi M. Neuroprotective role of polyphenols in treatment of neurological disorders: A review. Interventional Pain Medicine and Neuromodulation. 2021 Dec 31;1(1).

32. Maqbool M, Ara I, Gani I. The Story of Polycystic Ovarian Syndrome: A Challenging Disorder with Numerous Consequences for Females of Reproductive Age. International Journal of Current Research in Physiology and Pharmacology. 2022 Nov 28:19-31.

33. Maqbool M, Gani I. Utilization of statins in reducing comorbidities of diabetes mellitus: A systematic review. Journal of Pharmacy Practice and Community Medicine. 2018;4(4).

34. Maqbool R, Maqbool M, Zehravi M, Ara I. Acute neurological conditions during pregnancy and their management: a review. International Journal of Adolescent Medicine and Health. 2021 Aug 23;33(6):357-66.

35. Maqbool M, Tariq S, Amjad S. Prescribing practices in pediatrics and drug utilization studies promoting pediatric health. Indo American Journal of Pharmaceutical Sciences. 2018 Aug 1;5(8):8070-6.

36. Maqbool M, Naeem A, Aamer S. Diabetes mellitus and its various management strategies in practice. Indo American Journal of Pharmaceutical Sciences. 2018 Aug 1;5(8):8163-+.

37. Maqbool M, Shabbir W, Aamir S. Adverse events of blood transfusion and blood safety in clinical practice. Indo American Journal Of Pharmaceutical Sciences. 2018 Aug 1;5(8):8254-9.

38. Qadrie Z, Maqbool M, Dar MA, Qadir A. Navigating challenges and maximizing potential: Handling complications and constraints in minimally invasive surgery. Open Health. 2025 Feb 5;6(1):20250059.

39. Oral O, Maqbool M, Thapa P, Tatlibal P, Enser M. The potential impact of weight control management on metabolic health during healthy aging. Global Translational Medicine. 2025 Jan 13:4815.

40. Maqbool M, Oral O. Implications of hypothyroidism in females of reproductive age: a review of current literature.